[8-K] Serina Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Serina Therapeutics furnished a press release announcing its financial results for the quarter ended June 30, 2025. The current report states the press release is provided as Exhibit 99.1 and that the information is furnished, not filed, meaning it is not automatically incorporated by reference into other SEC filings.

This 8-K does not include the text of the financial results within the report itself; readers must consult Exhibit 99.1 for detailed revenue, expense, profitability or other performance metrics.

Insights

Securities Analyst

TL;DR: Routine furnishing of quarterly results; no financial metrics are included in this filing, limiting immediate investor assessment.

The company used an Item 2.02 disclosure to furnish a press release reporting quarter-end results for June 30, 2025. Because the filing itself does not present any revenue, expense, earnings or guidance figures, investors and analysts cannot evaluate performance or trends from this document alone. From an investor-impact perspective this is a neutral disclosure and is not impactful until the contents of Exhibit 99.1 are reviewed.

Corporate Governance Expert

TL;DR: The company clearly states the press release is furnished, not filed, which is standard disclosure practice and has limited governance implications.

Legally, Serina has followed customary procedure by furnishing the press release as Exhibit 99.1 and explicitly stating the material is not "filed" under Section 18. That preserves the company’s control over incorporation-by-reference in future filings. There is no mention of executive changes, material transactions, or amendments to prior disclosures in this report. Governance impact is therefore neutral and the filing is not impactful on its own.

0001708599false00017085992025-08-112025-08-11

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported): August 11, 2025

Serina Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

1-38519

82-1436829

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

601 Genome Way, Suite 2001

Huntsville, Alabama 35806

(Address of principal executive offices)

(256) 327-9630

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol

Name of exchange on which registered

Common Stock, par value $0.0001 per share

SER

NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition

On August 11, 2025, Serina Therapeutics, Inc issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 hereto.

The information in this Item 2.02 and in the press release furnished as Exhibit 99.1 to this current report shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 - Financial Statements and Exhibits.

Exhibit Number						Description
99.1						Press Release of Serina Therapeutics, Inc. issued on August 11, 2025
104						Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			SERINA THERAPEUTICS, INC.
Date: August 11, 2025			By:			/s/ Gregory S. Curhan
						Chief Financial Officer

FAQ

What did Serina Therapeutics (SER) disclose in this 8-K?

The company furnished a press release announcing its financial results for the quarter ended June 30, 2025, provided as Exhibit 99.1 to the current report.

Where can I find the detailed Q2 2025 financial results for SER?

The detailed results and commentary are contained in the press release attached as Exhibit 99.1 to this current report.

Is the press release considered 'filed' with the SEC?

No. The filing explicitly states the information is furnished, not filed, and therefore is not deemed filed under Section 18 and is not incorporated by reference except by specific reference.

Does this 8-K include full financial statements or tables?

No. Item 9.01 lists the press release as Exhibit 99.1 and a cover page interactive data file (104); the body of the report does not include full financial statements.

Does the report disclose material transactions or management changes?

The report only furnishes a press release reporting quarterly results and does not disclose any transactions or executive changes in the text of this filing.